Meckel's diverticulum leading to axial torsion and volvulus of the small bowel.

BMJ Case RepOct 7, 2026 (epub)
Case ReportGeneral SurgeryGastroenterology

Fabian Wehrmann, Niamh Keating, Munir Saeed

✦ AI-curated · Sources linked

Case in brief

A patient presented with small-bowel obstruction caused by a giant Meckel’s diverticulum measuring 22 cm × 11 cm × 9.8 cm. The diverticulum produced mass effect and was associated with axial torsion and volvulus of the small bowel. The patient underwent emergency laparotomy, resection of the affected bowel and primary anastomosis.

What made this case unusual

The diverticulum’s giant size and mass effect were associated with axial torsion and small-bowel volvulus, an unusual complication pattern.

Diagnostic / clinical pearl

Meckel’s diverticulum can present as small-bowel obstruction with volvulus, including when a giant diverticulum causes mass effect.

Source

PubMed · PMID 42843916

Published in BMJ Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.